What is GLP-1? The hormone you already make, explained plainly

¿Qué es el GLP-1? La hormona que ya fabricas, explicada sin rodeos

You have probably heard the term — in the news, on TikTok, from a cousin who lost weight. GLP-1. It sounds like a lab code.

The first thing worth knowing is the part the headlines skip: GLP-1 is not a medication. It is a hormone your body already makes, every day, every time you eat. You are making it right now.

What changed in recent years was not the discovery of the hormone. It was learning to build a version that lasts — and then finding out, in trials with tens of thousands of people, what happens when that signal stays switched on.

This article covers both: what the hormone does, and what the studies showed. With the real numbers, including the uncomfortable ones.

The hormone: what it is and what it does

Your gut is not just a tube food passes through. It is an organ that talks. It has cells along its wall that detect what is arriving — sugars, fats, proteins — and respond by releasing chemical messengers into the blood.

GLP-1 is one of those messengers. It is made by cells called L cells, concentrated mostly in the last part of the small intestine and the colon. They start releasing it within minutes of you starting to eat.

And the message it carries is essentially: food has arrived, everyone get organized. That order gets carried out in three different places:

1. In the pancreas

It tells the pancreas to release insulin, the hormone that moves glucose into cells. But with a crucial detail: it does this only when blood sugar is high. If your glucose is normal, GLP-1 does not force insulin out.

This is called a glucose-dependent effect, and it is why these medications, on their own, almost never cause low blood sugar. It is a brake with a sensor, not a brake pressed to the floor.

At the same time it suppresses glucagon, the opposing hormone, the one that asks the liver to release stored sugar. It pushes in both directions at once.

2. In the stomach

It slows gastric emptying: food leaves the stomach more gradually on its way to the intestine.

This has two consequences you will feel. The good one: you get full sooner and stay full longer. The other one: if you overeat or eat very fast, your stomach complains, because it is literally working with the exit more closed than usual.

3. In the brain

This is the part that changed the game, and the part everyone underestimated at first.

GLP-1 reaches brain regions that regulate appetite — the hypothalamus and the brainstem — acting on receptors sitting there waiting for it. The result is not "removing hunger" by force. It is something subtler: turning down the volume on your interest in food.

Why it lasts only two minutes

Here is the obstacle that took twenty years to solve, and understanding it explains everything else.

Your natural GLP-1 has a working life of roughly one to two minutes in the blood. An enzyme called DPP-4 circulates looking for exactly this molecule and cuts it the moment it finds it. It cuts at a specific point, and once cut, the message stops having any effect.

From the body's point of view this makes perfect sense: it is a "food just arrived" signal, and a signal like that has to switch off quickly so it can switch on again at the next meal.

From a treatment point of view, it is a disaster. You could inject natural GLP-1 all day and achieve nothing sustained.

How it became a medication

The solution was not inventing a new molecule. It was modifying the existing one so the enzyme could not recognize it, and adding an anchor that kept it circulating.

Change the exact spot where DPP-4 cuts, and the enzyme passes it by. Attach a fatty chain that binds to the albumin in your blood, and instead of your kidneys clearing it in minutes, it stays afloat for days. Result: from two minutes to a week.

That is it. That is why these medications are taken once a week: not because they are more potent per dose, but because the message no longer switches off.

Two generations, two locks

• Semaglutide activates the GLP-1 receptor. One key, one lock.
• Tirzepatide activates two: the GLP-1 receptor and also the GIP receptor — another gut hormone from the same family, released higher up in the intestine, working on fat and metabolism through somewhat different pathways.

That second lock is why tirzepatide's numbers run higher. If the detailed comparison interests you, we cover it in semaglutide vs. tirzepatide.

Why the "food noise" goes quiet

There is a phrase people repeat when they start a program that describes what these medications do better than any chart: the noise went quiet.

"Food noise" is that background thought about food that will not switch off. You already ate, you are not physically hungry, and your head goes back to what is in the fridge anyway. That is not a character flaw. It is a biological signal playing louder than it should.

When the GLP-1 signal stays on, that volume drops. People do not describe "not being able to eat." They describe not thinking about eating so much. That is an important difference, and it explains why this works where willpower did not: it is not competing with the noise, it is lowering it.

We cover it separately in the article on food noise.

The numbers from the trials

This is where GLP-1 separates itself from nearly everything else sold for weight loss. These are not testimonials. They are randomized, placebo-controlled trials with thousands of people.

STEP 1 — semaglutide 2.4 mg

1,961 adults with obesity, or overweight plus a weight-related condition, without diabetes. Double-blind, 68 weeks, with lifestyle intervention in both groups.

And what the per-person percentages say, which is usually more useful than the average:

In the placebo group, those figures were 31.5%, 12.0% and 4.9%.

SURMOUNT-1 — tirzepatide

2,539 adults with obesity, also without diabetes. 72 weeks, three doses against placebo.

At 15 mg, 57% of participants lost 20% or more of their body weight. In the placebo group, 3% did.

A number like that, from an injected medication, did not exist before in the history of weight management.

The surprise: the heart

Weight loss was already the goal. What came next was not guaranteed.

The SELECT trial followed 17,604 people aged 45 or older, all with preexisting cardiovascular disease and overweight or obesity, but without diabetes. Weekly semaglutide 2.4 mg against placebo, with nearly four years of mean follow-up.

That changed the entire conversation. It stopped being a medication about the number on the scale and became a medication with a hard outcome measured: fewer heart attacks and fewer strokes.

Stated precisely: the trial was done in people who already had heart disease. It does not demonstrate the same benefit in a healthy 32-year-old wanting to lose ten pounds. That distinction matters.

What happens when you stop

This section is the main reason we rewrote this article, because it is the part omitted from almost everything you will read on the subject.

A group of STEP 1 participants was followed for one more year after stopping both the medication and the lifestyle program.

They had lost 17.3% of their weight. One year after stopping, they had regained 11.6 percentage points of that loss. They ended up 5.6% below their starting weight.

The authors' own conclusion is direct: the findings confirm that obesity is a chronic condition and that ongoing treatment is required to maintain the improvements.

This is not a flaw in the medication. It is what any treatment for a chronic condition does. Nobody is surprised when blood pressure rises after stopping blood pressure medication. With weight, though, we still expect the cure to be permanent after a while.

But it is information you need before starting, not after. If you go in thinking three months, the math will not work out.

Side effects, specifically

In the trials, the most common effects were digestive: nausea and diarrhea, mostly while increasing the dose. In STEP 1 they were typically transient, mild to moderate, and subsided over time.

The figure that best measures how tolerable it was: in STEP 1, 4.5% discontinued treatment because of gastrointestinal effects, versus 0.8% on placebo. In SURMOUNT-1, discontinuations for adverse events ran between 4.3% and 7.1% depending on dose, against 2.6% with placebo.

Put another way: the large majority tolerated it. A real minority did not.

Other things monitored in clinic, which a good clinician will raise without you asking: constipation, reflux, fatigue in the first weeks, and the gallbladder question, because rapid weight loss — from any cause — raises the risk of gallstones.

The way to handle nearly all of it is the same: increase the dose slowly. It is not a race. We have a full guide in managing GLP-1 side effects.

The muscle question

When you lose weight, you do not lose only fat. Part of what goes is lean mass — muscle. That happens with any weight loss method, including diet alone, and it happens here too.

It matters for a practical reason: muscle is metabolically active tissue. Losing a lot of it leaves you weaker and with a slower metabolism, exactly when you need the opposite.

The two tools are well known and hold no mystery: enough protein at every meal and strength training two or three times a week. With appetite suppressed, hitting your protein takes more effort — it has to be planned.

We go into it in strength training on a GLP-1.

What this evidence does NOT say

It does NOT say it works the same for everyone. The numbers you read are averages. In those same trials, some people lost considerably more and some considerably less. Nobody can promise you your number.

It does NOT say this is for losing ten cosmetic pounds. The trials were done in people with obesity, or overweight plus a related condition. That is the group where the benefit was measured.

It does NOT say it replaces eating well and moving. Every one of these trials included lifestyle intervention in both arms, placebo included. The medication was measured on top of that, never instead of it.

It does NOT say it is forever, or that it is for three months. It says that while it is used, it works; and that on stopping, weight tends to return. How long makes sense in your case is a medical conversation, not a general rule.

It does NOT say the cardiovascular benefit applies to anyone. SELECT was done in people who already had heart disease. Extrapolating it to everyone goes beyond the data.

Who is this NOT for?

• If you have a personal or family history of medullary thyroid carcinoma or MEN2 syndrome.
• If you are pregnant, trying to conceive, or breastfeeding.
• If you have a history of pancreatitis, or active gallbladder disease.
• If you have gastroparesis or significant digestive disease — slowed emptying is already part of the problem.
• If you have or have had an eating disorder. A medication that removes appetite needs specialized support, not a web form.
• If what you expect is to keep sleeping badly, moving little and eating at all hours, and have the medication cover all of it. It helps a great deal. It does not perform magic.

Frequently asked questions

Is GLP-1 a hormone or a medication?

Both, which is why the name confuses people. GLP-1 is a hormone your gut makes after you eat. The medications — semaglutide, tirzepatide — are long-acting copies that activate the same receptor. When someone says "I'm on a GLP-1," they mean the medication.

How much weight do people lose?

In the trials, the average was 14.9% of body weight with semaglutide 2.4 mg at 68 weeks, and up to 20.9% with tirzepatide 15 mg at 72 weeks. Those are averages across thousands of people: your individual result may land above or below, and nobody can honestly predict it.

Will it cause low blood sugar?

On their own, almost never, because the insulin effect is glucose-dependent: it only acts when sugar is high. The risk appears when combined with insulin or certain diabetes pills, and that is precisely what the physician reviews.

Do I have to use it for life?

The data show that on stopping, about two-thirds of the lost weight returns within a year. That does not mean the answer is "forever" — it means stopping gets planned with a physician, the same way starting does.

Which is better, semaglutide or tirzepatide?

On average tirzepatide produced higher weight loss figures, but "better" depends on your history, your digestive tolerance, your conditions and your budget. It is exactly the kind of decision made with a clinician who has seen your case.

Can I take it if I don't have diabetes?

The STEP 1, SURMOUNT-1 and SELECT trials were done specifically in people without diabetes. Eligibility is determined by a medical evaluation, not by an article.

How we offer it

We wrote this article with one fixed idea: that by the time you reach this section you understand the hormone, the numbers and the fine print — including the part about weight coming back — and can decide for yourself.

Once you start your program, a licensed physician reviews your case — habits, stress, sleep and medical history — and orders labs only if they consider it necessary. Depending on your medical history and your state, the clinician may schedule a video visit with you if they consider it necessary.

From there:

• A prescription. Rx, from a physician licensed in your state.
• A licensed pharmacy. They prepare and dispense your order.
• Shipped straight to your door, in two days.
• A care team for your questions — especially in the first weeks, the nausea weeks.
• Recurring deliveries and dose adjustment with an optional monthly check-in.
• Cancel whenever you want, in one click.

We have GLP-1 programs with FDA-approved medications (Wegovy®, Foundayo™, Ozempic®) from $149/month, by telemedicine, in Spanish and English. And if, on reviewing your case, a different road makes more sense for you — thyroid, hormone health, or simply sorting out sleep and protein first — we will tell you, even when it does not suit us.

Eligibility is determined by medical evaluation. Individual results vary and are not guaranteed.

See the programs →

Sources

Articles located through PubMed.

• Wilding JPH, Batterham RL, Calanna S, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. N Engl J Med. 2021;384(11):989-1002. 10.1056/NEJMoa2032183
• Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide Once Weekly for the Treatment of Obesity. N Engl J Med. 2022;387(3):205-216. 10.1056/NEJMoa2206038
• Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. N Engl J Med. 2023;389(24):2221-2232. 10.1056/NEJMoa2307563
• Wilding JPH, Batterham RL, Davies M, et al. Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension. Diabetes Obes Metab. 2022;24(8):1553-1564. 10.1111/dom.14725
• Hammoud R, Drucker DJ. Beyond the pancreas: contrasting cardiometabolic actions of GIP and GLP1. Nat Rev Endocrinol. 2023;19(4):201-216. 10.1038/s41574-022-00783-3
• Drucker DJ. Prevention of cardiorenal complications in people with type 2 diabetes and obesity. Cell Metab. 2024;36(2):338-353. 10.1016/j.cmet.2023.12.018

Your trust is worth more than a sale.

More information →

This article is informational and is not medical advice. SCTS1 does not prescribe medication. All medical care, prescriptions and treatment plans are provided by licensed physicians through our partner platform, and preparations are dispensed by licensed pharmacies. Eligibility is determined by a licensed provider. Any treatment decision rests with a licensed physician evaluating your case. Individual results vary and are not guaranteed.